ELUT

In May 2026, Elutia Inc. announced it would report its first-quarter 2026 financial results on May 14, 2026. Insider trading activity was reported in April 2026. In March 2026, the company's price target was increased by 42.86% to $5.10, and they presented at Sidoti's Small-Cap Virtual Investor Conference. Full-year 2025 earnings were reported, with EPS exceeding expectations but revenues falling short, and a delisting risk was warned. A new risk related to revenue and earnings growth was identified. In October 2025, Elutia closed the $88 million cash sale of its BioEnvelope business to Boston Scientific Corporation. As of April 22, 2026, the stock price was $1.16 per share, a 49.34% decline from the previous year.